Introduction

Allergic rhinitis (AR) is a chronic condition induced by immune responses to inhaled allergens mediated by Immunoglobulin E (IgE). AR is a public health issue that causes a significant burden and injury worldwide. It also co-occurs with asthma and conjunctivitis. Inhalant and environmental allergens, as well as genetic factors, are risk factors. AR reduces the quality of living, has an effect on social life, education, and employment, and is correlated with significant economic costs. The most commonly used pharmacological treatments are oral, intranasal, or ocular H1-antihistamines, intranasal corticosteroids, or a fixed combination of intranasal H1-antihistamines and corticosteroids.

Pathophysiology

Inflammatory cells such as mast cells, CD4-positive T cells, B cells, macrophages, and eosinophils infiltrate the nasal lining when an inciting allergen is present. T helper 2 (Th2) T cells invade the nasal mucosa and release cytokines that help plasma cells develop IgE in allergic people. Allergic crosslinking of IgE on mast cells activates mediators such as histamine and leukotrienes, inducing pulmonary arteriolar dilation, increased artery permeability, itching, rhinorrhea, mucus secretion, and smooth muscle contraction. Over the next 4-8 hours, mediators and cytokines released during the early stages of an immune response to an initiating allergen induce a second cellular inflammatory response, resulting in a recurrence of symptoms (usually nasal congestion) that can last for days.

Classification

Allergic Rhinitis can be classified on the following basis:

Traditional Classification

Classified as seasonal or perennial, however, not all the patients can be categorized in this manner. Pollen, for example, is seasonal in colder climates but perennial in warmer climates, so patients with several seasonal allergies may experience symptoms throughout the year.

Based on etiology: IgE-mediated (allergic), autonomic, infectious, and idiopathic.

Based on the duration (intermittent or continuous) and severity (mild, moderate, or severe) of the symptoms: According to the criteria of Allergic Rhinitis and its Asthma Effect (ARIA), intermittent allergic rhinitis is defined as signs fewer than four days a week or for less than four consecutive weeks, and the symptoms of persevering allergic Rhinitis occur over a 4 day week period or for four consecutive weeks. If patients do not have sleep disruption and are in a condition to conduct everyday operations, their symptoms are mild. Symptoms are classified as moderate/severe whether they conflict significantly with sleep or with the day-to-day activities.

Additional Classifications

Occupational rhinitis: Inflammatory nose disorder caused by a complex work environment rather than external stimulation. Although the overall prevalence of occupational rhinitis is unknown, high-risk jobs include employees in laboratory or food production, veterinary surgeon, fisherman, and workers in different industrial sectors. Within the first two years of work, workplace
rhinitis typically occurs. It’s probable that the disease is IgE-mediated as a result of allergen sensitization or reaction to respiratory irritants. Symptoms may appear shortly after exposure to the inciting stimulus or several hours later. Ocular and pulmonary signs are often present. The normal history and physical assessment of a patient suspected of having occupational rhinitis, as well as site inspections and skin tests and the in-vitro screening of inhalants should be used. Avoiding damage to the causative agent and, if necessary, pharmacotherapy is the mainstay of treatment. Although it is probable, there is no indication that occupational rhinitis can lead to occupational asthma with prolonged exposure. As a result, if contamination cannot be removed but symptoms are sufficiently managed, patients are usually not recommended to abandon their work.

**Local allergic rhinitis:** In the absence of signs of systemic atopy, Local Allergic Rhinitis (LAR) is a pathological entity characterized by a localized allergic reaction in the nasal mucosa. Patients with LAR are subject to negative IgE and/or in vitro testing but in the nasal mucosa, there is evidence of local IgE activity which also resolves severe nasal allergic problems. The consequences for LAR care are currently unclear, but some research indicates that allergen immunotherapy could be useful in this form of rhinitis.

**Diagnosis**

AR is detected by taking a complete patient history and applying it to test findings (physical examination and, if necessary, nasal endoscopy) and allergen-specific IgE screening, if necessary. Additional tests can be undertaken to monitor or exclude different forms of rhinitis, including nasal allergen challenges, CT tests, and assessment for nasal oxide or ciliary beat quantities, assessments for nasal stain, culture, and inspection for transferrin.

**Prevention**

Many efforts have been made to eliminate allergic disorders, but the majority of these attempts have failed. On the other hand, in countries with high revenues and perhaps lower medium-income countries, farm animal exposure in childhood frequently constitutes a preventive element in allergic diseases, but the mechanisms remain unclear. Moreover, early introduction to cats and dogs can help prevent allergies from developing, but the findings differ.

**Treatment**

The aim of treatment for allergic rhinitis is to alleviate symptoms. Accessible treatment choices include avoidance measures, nasal saline drainage, oral antihistamines, intranasal corticosteroid/antihistamine mixture, Leukotriene Receptor Antagonist (LTRA) and Allergic Immunotherapy (AAID). Decongestants and oral corticosteroids are two other drugs that may be effective in some patients. An allergist should be considered whether the symptoms of the patient persist after careful care.